Warren Buffett's Favorite Valuation Indicator Blew Past the Level He Warned Was "Playing With Fire." Here Are 3 Stocks Still Cheap Enough to Buy.

The Buffett indicator is 235.8%, above Buffett’s historical 200% warning level, but the article argues that Enterprise Products Partners, JPMorgan Chase and Pfizer remain attractively valued. Enterprise reported latest-quarter earnings up 28% year over year and offers a distribution yield above 6%; JPMorgan trades at 13.5 times forward earnings, while Pfizer trades at 9.7 times and yields over 6.3%. The article highlights Enterprise’s exposure to fuel demand from AI data centers and Pfizer’s patent-cliff risk, while noting Pfizer expects high-single-digit revenue CAGR after the worst of the cliff passes in 2028.

Analysis

The Buffett indicator is a poor near-term timing tool and says little about whether these three cash-flow profiles are mispriced; its practical implication is to demand a margin of safety and favor company-specific catalysts over broad multiple expansion. EPD has the clearest fundamental linkage to AI, but data-center electricity demand is not equivalent to incremental EPD earnings: the conversion depends on gas-fired generation, regional pipeline constraints, contract economics, and project execution. A high distribution yield is attractive only if coverage and leverage remain sound as growth projects are funded. Over 6–18 months, infrastructure bottlenecks could support midstream volumes, while competing generation sources or delayed buildouts would weaken the thesis.

JPM is not a simple “rates up, earnings up” exposure. The key near-term swing factor is whether asset yields reprice faster than deposit costs; a flatter curve, deposit competition, or worsening credit could offset higher reinvestment income. Prefer it on evidence of stable deposit pricing and resilient credit rather than the rate direction alone.

PFE’s valuation embeds a difficult earnings transition, but the dividend does not remove the risk that cash generation and pipeline execution disappoint. The patent pressure is also relevant to Bristol-Myers Squibb through Eliquis, so a PFE-only framing may understate the competitive and revenue-overlap effects. The claimed post-cliff growth path needs validation against product launches, pipeline data, and cash-flow guidance. Near-term income support could limit downside, but does not establish a durable floor.

Key Decisions for Investors

• EPD: Consider a staged long on weakness, not a chase based on AI headlines. Before adding, verify distribution coverage, leverage, committed project returns, and contracted volumes; reduce or exit if coverage deteriorates or expected infrastructure demand is deferred.
• JPM: Keep as a conditional long/watch rather than a direct rates trade. Add only if deposit-cost growth remains contained and credit metrics hold; the thesis is falsified by deposit repricing that outruns asset yields or a material deterioration in loan performance.
• PFE: Avoid treating the yield as a standalone buy signal. Wait for evidence that pipeline launches and post-cliff guidance can support cash generation and the dividend; monitor Bristol-Myers Squibb as a related exposure to Eliquis erosion.
• Portfolio-level: Use the elevated market-valuation backdrop as a sizing and entry-discipline signal, not a reason to short these names indiscriminately. Reassess on earnings revisions, not the Buffett indicator alone.